Mr. Jeffrey Yordon, President of Athenex Pharmaceutical Division, stated, "We are excited to have this opportunity to partner with SunGen Pharma and their unique business model. The combination of Athenex's sales, marketing, regulatory and quality infrastructure, combined with SunGen Pharma's product development expertise and broad partnering network around the world, make for a formidable combination of skill sets. The SunGen Pharma partnership, one of many partnerships we plan on executing in the near term, will supply high value products to our markets. We are pleased to be working with an organization of SunGen Pharma's caliber. The emphasis on product selection with SunGen Pharma and other future partners in oncology will complement our robust proprietary pipeline of oral oncolytics. Opportunities like this enable Athenex to add to our infrastructure of our own sales, marketing and distribution systems prior to the launch of our first proprietary oncology product."
Dr. Isaac Liu, Co-CEO and President of SunGen Pharma, stated, "SunGen Pharma is very pleased to be a significant partner of Athenex. We have worked with Mr. Yordon in the past and are very confident that our joint venture will be extremely successful. Furthermore, we believe our extensive network of companies around the world will result in additional products and opportunities for this joint venture."
The specialty products being launched in the near term are expected to create a revenue and margin contribution to help subsidize the ongoing clinical trials and research and development projects for the Athenex proprietary pipeline. To further the synergies, Athenex will be working closely with its Active Pharmaceutical Ingredient (API) division, Polymed, to back-integrate into its pipeline of products. The company fully expects to consummate several more of these types of transactions in the near future.
About Athenex, Inc.
Founded in 2003, Athenex is a global innovative pharmaceutical company focused on the development and commercialization of next generation therapies for cancer diseases and supportive therapies with a particular emphasis on the China and U.S. markets. The company is dedicated to delivering innovative drugs that can have a life-changing impact on cancer patients. The Athenex business includes: three portfolios of innovative proprietary products under development, medical technology research innovation centers, product development and regulatory teams, and existing manufacturing facilities in China and the U.S. Athenex employees include several hundred professionals dedicated to the mission of improving the lives of cancer patients throughout the world. With a connected innovation, development and manufacturing presence concentrated in China and the U.S., Athenex can identify, develop, and deliver unique medical technology across continents and multiple regulatory environments. Athenex has offices in Buffalo and Clarence New York, Cranford New Jersey, Hong Kong, Taipei Taiwan, and multiple locations in Chongqing, China. In addition to their offices, Athenex has regional development partners in Dunedin New Zealand, Hong Kong, Guangzhou China, Seoul South Korea, Taipei Taiwan, Guatemala City, Guatemala, and Buenos Aires, Argentina.
About SunGen Pharma LLC DBA Peterson Pharmaceuticals
SunGen Pharma LLC DBA Peterson Pharmaceuticals is a privately held specialty pharmaceutical company which develops, contract manufactures, and sells pharmaceutical finished products. SunGen specializes in the development of oral solid extended release, complex injectable products, patch, cream and ointment, and other high entry barrier products. SunGen has business partnerships with many US based and global pharmaceutical companies to develop, manufacture, and sell pharmaceutical products around the world.
For more information about Athenex's portfolio of proprietary products and clinical studies, please visit www.athenex.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/athenex-inc-and-sungen-pharma-enter-into-us-joint-venture-agreement-for-a-portfolio-of-7-approved-pharmaceutical-products-300334134.html
SOURCE Athenex, Inc.